Corpovael, S.A.B. de C.V. Logo

Corpovael, S.A.B. de C.V.

CADUA.MX

(2.5)
Stock Price

3,50 MXN

3.79% ROA

7.66% ROE

2.38x PER

Market Cap.

916.023.640,00 MXN

45.13% DER

0% Yield

8.63% NPM

Corpovael, S.A.B. de C.V. Stock Analysis

Corpovael, S.A.B. de C.V. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Corpovael, S.A.B. de C.V. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.18x), the stock offers substantial upside potential at a bargain price.

2 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

3 ROE

The stock's ROE falls within an average range (6.01%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (2.77%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

5 DER

The stock maintains a fair debt to equity ratio (52%), indicating a reasonable balance between the money it owes and the ownership it possesses.

6 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

7 Net Profit Growth

The net profit of this company has shown steady growth over the past three years, highlighting its positive financial trajectory and making it an appealing choice for potential investors.

8 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-15) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Corpovael, S.A.B. de C.V. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Corpovael, S.A.B. de C.V. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Sell
4 Stoch RSI Hold

Corpovael, S.A.B. de C.V. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Corpovael, S.A.B. de C.V. Revenue
Year Revenue Growth
2011 1.702.700.000
2012 1.907.824.000 10.75%
2013 2.607.704.000 26.84%
2014 3.189.490.000 18.24%
2015 3.523.021.000 9.47%
2016 4.021.668.000 12.4%
2017 4.507.213.000 10.77%
2018 4.846.430.000 7%
2019 4.303.626.000 -12.61%
2020 3.297.431.000 -30.51%
2021 2.778.531.000 -18.68%
2022 3.726.925.000 25.45%
2023 4.675.424.000 20.29%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Corpovael, S.A.B. de C.V. Research and Development Expenses
Year Research and Development Expenses Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Corpovael, S.A.B. de C.V. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 150.996.000
2012 168.137.000 10.19%
2013 270.742.000 37.9%
2014 291.866.000 7.24%
2015 331.262.000 11.89%
2016 387.887.000 14.6%
2017 446.687.000 13.16%
2018 521.385.000 14.33%
2019 159.224.000 -227.45%
2020 48.164.000 -230.59%
2021 46.774.000 -2.97%
2022 11.133.000 -320.14%
2023 471.844.000 97.64%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Corpovael, S.A.B. de C.V. EBITDA
Year EBITDA Growth
2011 360.273.000
2012 418.506.000 13.91%
2013 474.614.000 11.82%
2014 509.982.000 6.94%
2015 639.483.000 20.25%
2016 805.572.000 20.62%
2017 978.089.000 17.64%
2018 1.067.527.000 8.38%
2019 910.963.000 -17.19%
2020 287.516.000 -216.84%
2021 131.767.000 -118.2%
2022 431.713.000 69.48%
2023 562.432.000 23.24%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Corpovael, S.A.B. de C.V. Gross Profit
Year Gross Profit Growth
2011 506.269.000
2012 573.249.000 11.68%
2013 734.152.000 21.92%
2014 790.323.000 7.11%
2015 948.324.000 16.66%
2016 1.149.547.000 17.5%
2017 1.374.616.000 16.37%
2018 1.540.823.000 10.79%
2019 1.386.395.000 -11.14%
2020 777.921.000 -78.22%
2021 684.777.000 -13.6%
2022 947.780.000 27.75%
2023 1.282.712.000 26.11%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Corpovael, S.A.B. de C.V. Net Profit
Year Net Profit Growth
2011 228.595.000
2012 278.959.000 18.05%
2013 290.872.000 4.1%
2014 333.800.000 12.86%
2015 428.012.000 22.01%
2016 581.361.000 26.38%
2017 710.982.000 18.23%
2018 825.190.000 13.84%
2019 515.613.000 -60.04%
2020 151.649.000 -240%
2021 -103.636.000 246.33%
2022 258.963.000 140.02%
2023 340.204.000 23.88%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Corpovael, S.A.B. de C.V. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 1
2012 1 0%
2013 1 0%
2014 3 100%
2015 2 0%
2016 2 0%
2017 2 0%
2018 2 0%
2019 2 -100%
2020 0 0%
2021 0 0%
2022 1 0%
2023 1 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Corpovael, S.A.B. de C.V. Free Cashflow
Year Free Cashflow Growth
2011 136.882.000
2012 89.187.000 -53.48%
2013 309.022.000 71.14%
2014 -124.468.000 348.27%
2015 -422.758.000 70.56%
2016 -492.576.000 14.17%
2017 213.210.000 331.03%
2018 -194.750.000 209.48%
2019 390.924.000 149.82%
2020 769.700.000 49.21%
2021 283.748.000 -171.26%
2022 1.007.218.000 71.83%
2023 431.487.000 -133.43%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Corpovael, S.A.B. de C.V. Operating Cashflow
Year Operating Cashflow Growth
2011 145.969.000
2012 109.534.000 -33.26%
2013 318.800.000 65.64%
2014 -83.185.000 483.24%
2015 -421.366.000 80.26%
2016 -480.524.000 12.31%
2017 238.776.000 301.24%
2018 -160.915.000 248.39%
2019 390.924.000 141.16%
2020 769.700.000 49.21%
2021 283.748.000 -171.26%
2022 1.007.218.000 71.83%
2023 427.644.000 -135.53%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Corpovael, S.A.B. de C.V. Capital Expenditure
Year Capital Expenditure Growth
2011 9.087.000
2012 20.347.000 55.34%
2013 9.778.000 -108.09%
2014 41.283.000 76.31%
2015 1.392.000 -2865.73%
2016 12.052.000 88.45%
2017 25.566.000 52.86%
2018 33.835.000 24.44%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 -3.843.000 100%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Corpovael, S.A.B. de C.V. Equity
Year Equity Growth
2011 845.204.000
2012 966.363.000 12.54%
2013 1.041.818.000 7.24%
2014 1.275.618.000 18.33%
2015 3.206.152.000 60.21%
2016 3.497.547.000 8.33%
2017 3.984.418.000 12.22%
2018 4.664.538.000 14.58%
2019 4.836.907.000 3.56%
2020 4.973.212.000 2.74%
2021 4.734.402.000 -5.04%
2022 4.994.860.000 5.21%
2023 5.154.977.000 3.11%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Corpovael, S.A.B. de C.V. Assets
Year Assets Growth
2011 2.103.962.000
2012 2.376.361.000 11.46%
2013 2.824.467.000 15.87%
2014 3.350.037.000 15.69%
2015 5.509.502.000 39.2%
2016 6.335.939.000 13.04%
2017 7.632.000.000 16.98%
2018 9.356.102.000 18.43%
2019 10.012.180.000 6.55%
2020 10.014.243.000 0.02%
2021 10.127.211.000 1.12%
2022 10.427.431.000 2.88%
2023 10.016.821.000 -4.1%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Corpovael, S.A.B. de C.V. Liabilities
Year Liabilities Growth
2011 1.255.699.000
2012 1.407.044.000 10.76%
2013 1.775.340.000 20.75%
2014 2.062.008.000 13.9%
2015 2.284.581.000 9.74%
2016 2.815.383.000 18.85%
2017 3.592.854.000 21.64%
2018 4.691.564.000 23.42%
2019 5.175.273.000 9.35%
2020 5.041.031.000 -2.66%
2021 5.392.809.000 6.52%
2022 5.432.571.000 0.73%
2023 4.861.844.000 -11.74%

Corpovael, S.A.B. de C.V. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
13.98
Net Income per Share
1.21
Price to Earning Ratio
2.38x
Price To Sales Ratio
0.21x
POCF Ratio
0.49
PFCF Ratio
0.5
Price to Book Ratio
0.18
EV to Sales
0.61
EV Over EBITDA
4.49
EV to Operating CashFlow
1.47
EV to FreeCashFlow
1.47
Earnings Yield
0.42
FreeCashFlow Yield
1.99
Market Cap
0,92 Bil.
Enterprise Value
2,69 Bil.
Graham Number
20.98
Graham NetNet
-8.74

Income Statement Metrics

Net Income per Share
1.21
Income Quality
4.61
ROE
0.08
Return On Assets
0.04
Return On Capital Employed
0.1
Net Income per EBT
0.87
EBT Per Ebit
0.6
Ebit per Revenue
0.17
Effective Tax Rate
0.12

Margins

Sales, General, & Administrative to Revenue
0.03
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.28
Operating Profit Margin
0.17
Pretax Profit Margin
0.1
Net Profit Margin
0.09

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
5.8
Free CashFlow per Share
5.8
Capex to Operating CashFlow
-0
Capex to Revenue
-0
Capex to Depreciation
-0.03
Return on Invested Capital
0.09
Return on Tangible Assets
0.04
Days Sales Outstanding
0
Days Payables Outstanding
142.21
Days of Inventory on Hand
362.48
Receivables Turnover
0
Payables Turnover
2.57
Inventory Turnover
1.01
Capex per Share
-0

Balance Sheet

Cash per Share
1,68
Book Value per Share
16,21
Tangible Book Value per Share
16.36
Shareholders Equity per Share
16.21
Interest Debt per Share
7.78
Debt to Equity
0.45
Debt to Assets
0.23
Net Debt to EBITDA
2.96
Current Ratio
2.01
Tangible Asset Value
5,15 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
0.45
Working Capital
2,46 Bil.
Intangibles to Total Assets
0
Average Receivables
0,85 Bil.
Average Payables
1,09 Bil.
Average Inventory
3824000000
Debt to Market Cap
2.52

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Corpovael, S.A.B. de C.V. Dividends
Year Dividends Growth
2016 1
2017 1 0%
2018 76 100%
2019 1 -7400%

Corpovael, S.A.B. de C.V. Profile

About Corpovael, S.A.B. de C.V.

Corpovael, S.A.B. de C.V. engages in the design, urbanization, construction, marketing, and commercialization of residential homes in Mexico. The company was founded in 2001 and is based in Cancun, Mexico.

CEO
Mr. Pedro Vaca Elguero
Employee
9
Address
Corporativo Malecon Americas
Cancun, 77503

Corpovael, S.A.B. de C.V. Executives & BODs

Corpovael, S.A.B. de C.V. Executives & BODs
# Name Age
1 Adrian Ramirez Gallegos
Managing Director of Queretaro
70
2 Gustavo Castorena Moreno
Comptroller General
70
3 Mr. Pedro Vaca Elguero
Chairman of the Board & Chief Executive Officer
70
4 Mr. Mauricio Torres Pimienta
Chief Financial Officer & Director
70
5 Mr. Joaquin Vaca Elguero
Secretary of the Board, Equity Director & GM of Jalisco Branch
70
6 Mr. Pablo Vaca Elguero
General Director Construction Companies
70
7 Mr. Israel Godina Machado
Chief Legal Officer & Secretary of the Board
70
8 Mr. Manuel Araiza Luevano
Chief Operating Officer
70
9 Cesar Navarro Troncoso
Investor Relations Officer
70

Corpovael, S.A.B. de C.V. Competitors